Companies and Markets
Market Research A to Z | Company Profiles A to Z | Register | Contact Us
+44 (0) 203 086 8600 Call us on

Monoclonal Antibodies in Cancer Therapy 2009-2024

1499

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,499.00

Change Currency

GBP EURO USD

Market

Healthcare and Medical

Report Type

Market Research

Country

Global

Published

7 May 2009

Number of Pages

97

Report Delivery

Email

Delivery Lead Time

1-3 hours, 24 hour max

Publisher

Visiongain

File Format

PDF

Monoclonal antibodies in cancer therapy - significant commercial opportunities with developing technologies and innovative products - our new report explains prospects

Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains. The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies. The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both developed and emerging geographical markets. Currently, new technologies are removing some of the drawbacks that monoclonal antibody therapies have experienced. Leading pharma companies are already investing heavily in monoclonal antibody technologies. Monoclonal antibodies with great commercial potential are in the oncology pipeline, as our new report - Monoclonal Antibodies in Cancer Therapy 2009-2024 - also explains.

The period 2009 to 2019 will reveal volatility in the monoclonal antibody therapies market as current-leading products reach peak sales and new-generation drugs emerge. Will technological advances further benefit monoclonal antibody-based therapies and their overall sales? Will better immunotoxicity profiles lead to higher revenues for products? What types of monoclonal antibody therapies will enter the market from 2009 onwards, and can they dominate this market? Where will the opportunities lie, and what are the market drivers and restraints? This report will provide you with the information that you need to understand current trends and future possibilities. In particular, we discuss prospects for the following products:
• Rituxan
• Avastin
• Herceptin
• Erbitux
• Vectibix
• Campath.

Comprehensive analysis of this important market area

Monoclonal Antibodies in Cancer Therapy 2009-2024 examines that market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures included. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion.



Why you should buy this report

Benefits that you will gain from Monoclonal Antibodies in Cancer Therapy 2009-2024 include:
• Appraisal of the existing market for monoclonal antibody cancer therapies
• Forecasting and discussion of market values for monoclonal antibody cancer therapies, including detailed sales forecasts for 2009 to 2024
• Discussion of leading products, including sales forecasts, growth and market share analyses
• Analyses of 10 leading national markets for monoclonal antibody cancer therapies, including China and India, with forecasted sales and market shares
• Coverage of R&D pipeline developments, with trends to watch out for
• Exclusive interviews with a leading academic and mAbs journal chief editor and with a chief scientist in oncology within a leading pharma company
• Informed analyses of strengths and weaknesses of the technologies from 2009 onwards
• Balanced assessments of commercial drivers and restraints that the market area faces from 2009 to 2024.

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

Electronic License

Electronic License

An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.

Site License

Site License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.

Corporate License

Corporate License

An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£1,499.00

Change Currency

GBP EURO USD

Visitor Comments

All posts are pre-moderated and must obey the house rules.

Change Currency

GBP
USD

Use our research skills: Get free support

Free Research Support: Let us do the work for you and find information from public and private sources of information. Contact us now and we can save you time and money.......Free Research Support

eBrandPromote: Get your brands ranked highly online

eBrandPromote: Let us promote your brand online through article writing, press release distribution, social media and search engine marketing services. Click here to download our eBrandPromote brochure.

Accessibility
Close

Contrast settings

Text size settings